Findings from a meta-analysis of seven studies.

Results from the UK biobank involving 456,748 participants.

SUSTAIN-1 data support continued esketamine with an antidepressant after remission.

Results align with prior research.

Studies had shown conflicting results.

Recent AAP recommendations suggest screening for adverse childhood experiences.

Only 12% of those with depressive symptoms were receiving treatment.

Prior studies had suggested that long-term or high-dose benzodiazepines may impair cognitive function in MDD.

Systematic review largely finds little relationship between the two.

Healthy diet shows a protective effect against depression symptoms in older adults.

More questions than answers remain about the drug and route, says editorial.

Visceral hypersensitivity, psychological factors add in cumulative fashion.

Elevated depressive symptoms are common in these older adults.

Associations were stronger in prospective vs retrospective cohort studies.